{"date":"2026-04-02","count":17,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4771-2026-04-02-1909-16g7qjx","company_id":"4771","company":"望隼","market":"上市","industry":"生技醫療","date":"2026-04-02","time":"19:09:36","subject":"公告本公司初次申請股票上市時所出具之承諾事項暨其後續執行情形","clause":"第51款","fact_date":"2026-04-02","cite_as":"公開資訊觀測站重大訊息：望隼（4771），2026-04-02 19:09，「公告本公司初次申請股票上市時所出具之承諾事項暨其後續執行情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7427-2026-04-02-1836-5flzk1","company_id":"7427","company":"華上生醫","market":"興櫃","industry":"生技醫療","date":"2026-04-02","time":"18:36:20","subject":"公告本公司董事會決議召開115年股東常會相關事宜(新增議案)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：華上生醫（7427），2026-04-02 18:36，「公告本公司董事會決議召開115年股東常會相關事宜(新增議案)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6659-2026-04-02-1813-1twv6yz","company_id":"6659","company":"天明製藥","market":"興櫃","industry":"生技醫療","date":"2026-04-02","time":"18:13:20","subject":"代孫公司湖北香連藥業有限責任公司公告辦理減資變更登記完成。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：天明製藥（6659），2026-04-02 18:13，「代孫公司湖北香連藥業有限責任公司公告辦理減資變更登記完成。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1784-2026-04-02-1802-1eoh3c5","company_id":"1784","company":"訊聯","market":"上櫃","industry":"生技醫療","date":"2026-04-02","time":"18:02:50","subject":"衛福部核准願麗醫美診所與本公司合作之「自體脂肪幹細胞治療皮下及軟組織缺損」細胞治療技術施行計畫","clause":"第53款","fact_date":"2026-04-02","cite_as":"公開資訊觀測站重大訊息：訊聯（1784），2026-04-02 18:02，「衛福部核准願麗醫美診所與本公司合作之「自體脂肪幹細胞治療皮下及軟組織缺損」細胞治療技術施行計畫」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6543-2026-04-02-1735-ch9d8x","company_id":"6543","company":"普惠醫工","market":"興櫃","industry":"生技醫療","date":"2026-04-02","time":"17:35:50","subject":"公告本公司訂定一一四年下半年度現金股利分派相關事宜","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：普惠醫工（6543），2026-04-02 17:35，「公告本公司訂定一一四年下半年度現金股利分派相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6919-2026-04-02-1639-1w6raia","company_id":"6919","company":"康霈*","market":"上市","industry":"生技醫療","date":"2026-04-02","time":"16:39:40","subject":"公告本公司115年第一季合併財務報告董事會預計召開日期為115年4月10日","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：康霈*（6919），2026-04-02 16:39，「公告本公司115年第一季合併財務報告董事會預計召開日期為115年4月10日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4155-2026-04-02-1617-1qkz1x4","company_id":"4155","company":"訊映","market":"上市","industry":"生技醫療","date":"2026-04-02","time":"16:17:58","subject":"代重要子公司PRODIGY DIABETES CARE, LLC.公告現金股利配發基準日","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：訊映（4155），2026-04-02 16:17，「代重要子公司PRODIGY DIABETES CARE, LLC.公告現金股利配發基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4155-2026-04-02-1617-124ffeh","company_id":"4155","company":"訊映","market":"上市","industry":"生技醫療","date":"2026-04-02","time":"16:17:35","subject":"代重要子公司PRODIGY DIABETES CARE, LLC.公告董事會決議發放現金股利","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：訊映（4155），2026-04-02 16:17，「代重要子公司PRODIGY DIABETES CARE, LLC.公告董事會決議發放現金股利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6936-2026-04-02-1613-5flzk1","company_id":"6936","company":"永鴻生技","market":"上市","industry":"生技醫療","date":"2026-04-02","time":"16:13:48","subject":"公告本公司董事會決議召開115年股東常會相關事宜(新增議案)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：永鴻生技（6936），2026-04-02 16:13，「公告本公司董事會決議召開115年股東常會相關事宜(新增議案)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6936-2026-04-02-1611-x9m98g","company_id":"6936","company":"永鴻生技","market":"上市","industry":"生技醫療","date":"2026-04-02","time":"16:11:51","subject":"董事會決議股利分派(更正)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：永鴻生技（6936），2026-04-02 16:11，「董事會決議股利分派(更正)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6838-2026-04-02-1546-lnj9s3","company_id":"6838","company":"台新藥","market":"上市","industry":"生技醫療","date":"2026-04-02","time":"15:46:42","subject":"公告本公司初次申請股票上市時所出具之承諾事項執行情形","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台新藥（6838），2026-04-02 15:46，「公告本公司初次申請股票上市時所出具之承諾事項執行情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6838-2026-04-02-1546-1qyogg2","company_id":"6838","company":"台新藥","market":"上市","industry":"生技醫療","date":"2026-04-02","time":"15:46:25","subject":"補公告本公司114年度財務報告董事會召開日期","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台新藥（6838），2026-04-02 15:46，「補公告本公司114年度財務報告董事會召開日期」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4169-2026-04-02-1500-1bkmvqk","company_id":"4169","company":"泰宗","market":"上市","industry":"生技醫療","date":"2026-04-02","time":"15:00:43","subject":"本公司辦理股票初次上市前現金增資收足股款暨現金增資基準日","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：泰宗（4169），2026-04-02 15:00，「本公司辦理股票初次上市前現金增資收足股款暨現金增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4131-2026-04-02-1455-1848i25","company_id":"4131","company":"浩泰","market":"上櫃","industry":"生技醫療","date":"2026-04-02","time":"14:55:58","subject":"代子公司八億實業股份有限公司公告董事會決議不分派114年度股利","clause":"第14款","fact_date":"2026-04-02","cite_as":"公開資訊觀測站重大訊息：浩泰（4131），2026-04-02 14:55，「代子公司八億實業股份有限公司公告董事會決議不分派114年度股利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4131-2026-04-02-1455-lcr2cg","company_id":"4131","company":"浩泰","market":"上櫃","industry":"生技醫療","date":"2026-04-02","time":"14:55:33","subject":"代子公司八億實業股份有限公司公告董事會決議召開115年股東常會事宜","clause":"第17款","fact_date":"2026-04-02","cite_as":"公開資訊觀測站重大訊息：浩泰（4131），2026-04-02 14:55，「代子公司八億實業股份有限公司公告董事會決議召開115年股東常會事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4736-2026-04-02-1144-1fqkmsr","company_id":"4736","company":"泰博","market":"上市","industry":"生技醫療","date":"2026-04-02","time":"11:44:48","subject":"澄清媒體報導","clause":"第51款","fact_date":"2026-04-02","cite_as":"公開資訊觀測站重大訊息：泰博（4736），2026-04-02 11:44，「澄清媒體報導」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1795-2026-04-02-0641-kc1z0g","company_id":"1795","company":"美時","market":"上市","industry":"生技醫療","date":"2026-04-02","time":"06:41:12","subject":"本公司董事會通過子公司Lotus InternationalPte.Ltd.取得Sandoz AG於菲律賓之所有業務並簽訂資產購買協議","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：美時（1795），2026-04-02 06:41，「本公司董事會通過子公司Lotus InternationalPte.Ltd.取得Sandoz AG於菲律賓之所有業務並簽」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}